Boston-based Omega Funds today announced the closing of its eighth fund with $647 million in capital commitments.

Omega Fund VIII, was oversubscribed and beat its $600 million target, reaching the hard cap. With Fund VIII, the firm will continue to execute its strategy of creating and investing in life sciences companies in the U.S. and Europe that target